Integra LifeSciences IART Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
- Integra LifeSciences (IART) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $28.69M in Q1 2026.
- How has Integra LifeSciences's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
- Integra LifeSciences's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) decreased by 16.1% year-over-year, from $34.19M to $28.69M.
- What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
- This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.